Identification of Four Mouse FcRn Splice Variants and FcRn-Specific Vesicles DOI Creative Commons
George Haddad, Judith Blaine

Cells, Journal Year: 2024, Volume and Issue: 13(7), P. 594 - 594

Published: March 29, 2024

Research into the neonatal Fc receptor (FcRn) has increased dramatically ever since Simister and Mostov first purified a rat version of receptor. Over years, FcRn been shown to function not only as that transfers immunity from mother fetus but also performs an array different functions include transport recycling immunoglobulins albumin in adult. Due its important cellular roles, several clinical trials have designed either inhibit/enhance or develop non-invasive therapeutic delivery system such fusion drugs IgG enhance inside cells. Here, we report accidental identification alternatively spliced variants both mouse human The four new splice are capable binding immunoglobulins' Fab portions. In addition, identified FcRn-specific vesicles which can be stored involved endosomal-lysosomal system. complexity offers significant potential design novel targeted therapeutics.

Language: Английский

Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions DOI Creative Commons
Jeremy W. Jacobs, Garrett S. Booth, Sheharyar Raza

et al.

American Journal of Hematology, Journal Year: 2024, Volume and Issue: 99(12), P. 2351 - 2366

Published: Sept. 26, 2024

Abstract The neonatal fragment crystallizable (Fc) receptor (FcRn) transports IgG across mucosal surfaces and the placenta protects from degradation. Numerous clinical trials are investigating therapeutic FcRn inhibition for various immune‐mediated neuromuscular rheumatologic conditions; however, also represents a potential therapy IgG‐mediated hematologic conditions (e.g., immune thrombocytopenia, autoimmune hemolytic anemia, thrombotic thrombocytopenic purpura, acquired hemophilia, red blood cell/platelet alloimmunization). Current evidence derived both in vitro vivo studies suggests that inhibitors effectively reduce total levels without impacting its production or altering of other immunoglobulin isotypes. Moreover, risk serious adverse events, including infections, appears to be lower than seen with commonly used immunomodulatory/immunosuppressive therapies, albeit setting limited trial data. Ultimately, additional include varied patient populations required prior incorporating these agents into standard treatment algorithms most conditions. However, based on pathophysiology disorders mechanism action inhibitors, may represent future novel strategy patients caused by antibodies.

Language: Английский

Citations

3
The role of immunoglobulin transport receptor, neonatal Fc receptor in mucosal infection and immunity and therapeutic intervention DOI
Shaoju Qian,

Danqiong Zhang,

Zishan Yang

et al.

International Immunopharmacology, Journal Year: 2024, Volume and Issue: 138, P. 112583 - 112583

Published: July 6, 2024

Language: Английский

Citations

2
Identification of Four Mouse FcRn Splice Variants and FcRn-Specific Vesicles DOI Creative Commons
George Haddad, Judith Blaine

Cells, Journal Year: 2024, Volume and Issue: 13(7), P. 594 - 594

Published: March 29, 2024

Research into the neonatal Fc receptor (FcRn) has increased dramatically ever since Simister and Mostov first purified a rat version of receptor. Over years, FcRn been shown to function not only as that transfers immunity from mother fetus but also performs an array different functions include transport recycling immunoglobulins albumin in adult. Due its important cellular roles, several clinical trials have designed either inhibit/enhance or develop non-invasive therapeutic delivery system such fusion drugs IgG enhance inside cells. Here, we report accidental identification alternatively spliced variants both mouse human The four new splice are capable binding immunoglobulins' Fab portions. In addition, identified FcRn-specific vesicles which can be stored involved endosomal-lysosomal system. complexity offers significant potential design novel targeted therapeutics.

Language: Английский

Citations

0